Form 4: Agenus Inc. Director Thomas L. Harrison Reports Stock Option Award

Director Thomas L. Harrison reports the acquisition of 7,500 stock options in Agenus Inc. on August 7, 2024.

Summary

• Thomas L. Harrison, a director of Agenus Inc., filed a Form 4 to report changes in beneficial ownership.
• On August 7, 2024, Mr. Harrison was awarded 7,500 stock options with an exercise price of $5.08.
• These options vest in three equal annual installments starting August 7, 2025, contingent upon continued service with the company.
• Following the transaction, Mr. Harrison directly owns 7,500 shares of common stock.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral to slightly positive event.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment from the director.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company. This is a standard compensation practice.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry, similar to companies like Gilead Sciences, Amgen, and Biogen.
• The vesting schedule of three years is also a common practice to ensure long-term commitment, aligning with industry standards for executive compensation.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with the company's long-term performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates